| ADMA Biologics is a biopharmaceutical and immunoglobulin company that manufactures, markets and develops plasma-derived biologics for the treatment of immune deficiencies and the prevention and treatment of certain infectious diseases. Co.'s marketed products consist of: Nabi-HB, which is indicated for the treatment of acute exposure to blood containing Hepatitis B surface antigen; and Bivigam, which is indicated for the treatment of primary humoral immunodeficiency. Co. is also developing a pipeline of plasma-derived therapeutics, including its key pipeline product candidate, RI-002, for the treatment of Primary Immune Deficiency Disease. We show 27 historical shares outstanding datapoints in our coverage of ADMA's shares outstanding history.|
Understanding the changing numbers of ADMA shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like ADMA versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching ADMA by allowing them to research ADMA shares outstanding history
as well as any other stock in our coverage universe.